Implante de válvula aórtica transcateter, una década de experiencia en el primer centro cardiovascular en Colombia

Vista sencilla de ítem
dc.contributor.advisorMendoza Beltrán, Fernán del Cristo
dc.contributor.authorRojas Perdomo, Juan David
dc.contributor.authorFuentes Perez, Carlos Alberto
dc.date.accessioned2024-07-24T14:06:46Z
dc.date.available2024-07-24T14:06:46Z
dc.date.issued2024-07
dc.description.abstractIntroducción: La estenosis aórtica (EA) severa es la principal patología estructural cardiaca. Hoy día, el reemplazo valvular aórtico transcateter (TAVR) se ha convertido en la intervención de elección en pacientes de riesgo quirúrgico alto y prohibitivo. Nuestro objetivo fue determinar la tasa de éxito de implante del dispositivo en pacientes sometidos a TAVR durante el periodo de enero de 2012 a diciembre de 2023. Métodos: Estudio observacional descriptivo tipo serie de casos de pacientes con EA severa que fueron llevados a TAVR entre 01 de enero del 2012 al 31 de diciembre de 2023. Se estratificaron los desenlaces compuestos de tasa de éxito técnico y tasa de éxito del dispositivo según la definición VARC-3. Asi mismo, se describieron las características clínicas, hemodinámicas y la frecuencia de complicaciones (ACV, marcapasos, lesiones vasculares, arritmias, sangrado, lesión renal aguda) en los pacientes de la cohorte. Resultados: 134 pacientes fueron incluidos. La mediana de edad fue 80 años. 70.16% eran pacientes con EA estadio D1, 8,9% D2 y 20.8% D3. Las principales comorbilidades fueron la hipertensión arterial (80.6%) y la enfermedad coronaria (46.3%). La mortalidad global fue 8.9%. La principal complicación fue la lesión renal aguda seguida por el requerimiento de marcapasos permanente y la presencia de parafugas valvulares evidenciadas en el 19.4%, 18.7% y 17.9% de los casos respectivamente. Se documentó en nuestra población, una tasa de éxito técnico del 96.2% y éxito del dispositivo del 80.5% según la definición VARC-3. Conclusión: La tasa de éxito del dispositivo fue observada en el 80.5% de los pacientes, datos similares a los reportados en la literatura, evidenciando la adecuada implementación y evolución del programa en nuestro centro.
dc.description.abstractenglishIntroduction: Severe aortic stenosis (AS) is the main structural cardiac pathology. Nowadays, transcatheter aortic valve replacement (TAVR) has become the preferred intervention in patients with high and prohibitive surgical risk. Our objective was to determine the success rate of device implantation in patients undergoing TAVR during the period from January 2012 to December 2023. Methods: Descriptive observational case series study of patients with severe AS who underwent TAVR between January 1 and 2, 2012, and December 31, 2023. Composite outcomes of technical success rate and device success rate were stratified according to the VARC-3 definition. Likewise, the clinical and hemodynamic characteristics and the frequency of complications (stroke, pacemaker, vascular lesions, arrhythmias, bleeding, acute kidney injury) in the patients in the cohort were described. Results: 134 patients were included. The median age was 80 years. 70.16% were patients with AS stage D1, 8.9% D2 and 20.8% D3. The main comorbidities were arterial hypertension (80.6%) and coronary artery disease (46.3%). The global mortality was 8.9%. The main complication was acute kidney injury followed by the requirement for a permanent pacemaker and the presence of valvular leaks, which were seen in 19.4%, 18.7% and 17.9% of cases, respectively. A technical success rate of 96.2% and a device success rate of 80.5% according to the VARC-3 definition were documented in our population. Conclusion: The device success rate was observed in 80.5% of the patients, data similar to those previously reported, evidencing the adequate implementation and evolution of the program in our center.
dc.description.degreelevelEspecializaciónspa
dc.description.degreenameEspecialista en Cardiología de Adultosspa
dc.format.mimetypeapplication/pdf
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/12717
dc.language.isoes
dc.publisher.facultyFacultad de Medicinaspa
dc.publisher.grantorUniversidad El Bosquespa
dc.publisher.programEspecialización en Cardiología Adultosspa
dc.relation.referencesWal P, Rathore S, Aziz N, Singh YK, Gupta A. Aortic stenosis: a review on acquired pathogenesis and ominous combination with diabetes mellitus. Egyptian Heart Journal. 2023 Dec 1;75(1):1–17.
dc.relation.referencesBaumgartner H, Hung J, Bermejo J, Chambers JB, BChir M, Edvardsen T, et al. EACVI/ASE CLINICAL RECOMMENDATIONS Recommendations on the Echocardiographic Assessment of Aortic Valve Stenosis: A Focused Update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. 2017;
dc.relation.referencesLee G, Chikwe J, Milojevic M, Wijeysundera HC, Biondi-Zoccai G, Flather M, et al. ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Eur Heart J. 2023 Mar 7;44(10):796–812.
dc.relation.referencesKumar V, Sandhu GS, Harper CM, Ting HH, Rihal CS. Transcatheter aortic valve replacement programs: Clinical outcomes and developments. J Am Heart Assoc. 2020 Apr 21;9(8).
dc.relation.referencesCribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis. Circulation. 2002 Dec 10;106(24):3006–8.
dc.relation.referencesBhogal S, Rogers T, Aladin A, Ben-Dor I, Cohen JE, Shults CC, et al. TAVR in 2023: Who Should Not Get It? Am J Cardiol. 2023 Apr 15;193:1–18.
dc.relation.referencesCormican D, Jayaraman A, Villablanca P, Ramakrishna H. TAVR Procedural Volumes and Patient Outcomes: Analysis of Recent Data. J Cardiothorac Vasc Anesth. 2020 Feb 1;34(2):545–50.
dc.relation.referencesWriting Committee Members, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021 Feb 2;77(4):450–500.
dc.relation.referencesBerger D. Evolution of a TAVR Program. Crit Care Nurs Q. 2018;41(4):360–8.
dc.relation.referencesMendoza F. Valvulopatías en insuficiencia cardiaca. ‘Lo que el internista debe saber’. ActA MédicA coloMbiAnA. 2016;41(3):8–17.
dc.relation.referencesGoody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, et al. Aortic Valve Stenosis. Arterioscler Thromb Vasc Biol. 2020 Apr 1;40(4):885–900.
dc.relation.referencesVahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart diseaseDeveloped by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022 Feb 12;43(7):561–632.
dc.relation.referencesLeon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010 Oct 21;363(17):1597–607.
dc.relation.referencesSmith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine. 2011 Jun 9;364(23):2187–98.
dc.relation.referencesNishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Jun 10;63(22).
dc.relation.referencesLeon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine. 2016 Apr 28;374(17):1609–20.
dc.relation.referencesReardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Søndergaard L, Mumtaz M, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. New England Journal of Medicine. 2017 Apr 6;376(14):1321–31.
dc.relation.referencesNishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017 Jun 20;135(25):e1159–95.
dc.relation.referencesMack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. New England Journal of Medicine. 2019 May 2;380(18):1695–705.
dc.relation.referencesPopma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. New England Journal of Medicine. 2019 May 2;380(18):1706–15.
dc.relation.referencesBana A. TAVR-present, future, and challenges in developing countries. Indian J Thorac Cardiovasc Surg. 2019 Jul 1;35(3):473–84.
dc.relation.referencesSøndergaard L, Popma JJ, Reardon MJ, Van Mieghem NM, Deeb GM, Kodali S, et al. Comparison of a complete percutaneous versus surgical approach to aortic valve replacement and revascularization in patients at intermediate surgical risk results from the randomized SURTAVI trial. Circulation. 2019 Oct 15;140(16):1296–305.
dc.relation.referencesPopma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. New England Journal of Medicine. 2019 May 2;380(18):1706–15.
dc.relation.referencesClaessen BE, Tang GHL, Kini AS, Sharma SK. Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement: A Review. JAMA Cardiol. 2021 Jan 1;6(1):102–12.
dc.relation.referencesGénéreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, et al. Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. J Am Coll Cardiol. 2021 Jun 1;77(21):2717–46.
dc.relation.referencesRouleau SG, Brady WJ, Koyfman A, Long B. Transcatheter aortic valve replacement complications: A narrative review for emergency clinicians.
dc.relation.referencesArnold S V., Zhang Y, Baron SJ, McAndrew TC, Alu MC, Kodali SK, et al. Impact of Short-Term Complications on Mortality and Quality of Life After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2019 Feb 25;12(4):362–9.
dc.relation.referencesAdams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. New England Journal of Medicine. 2014 May 8;370(19):1790–8.
dc.relation.referencesPibarot P, Herrmann HC, Wu C, Hahn RT, Otto CM, Abbas AE, et al. Standardized Definitions for Bioprosthetic Valve Dysfunction Following Aortic or Mitral Valve Replacement: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022 Aug 2;80(5):545–61.
dc.relation.referencesGrube E, Sinning JM. The “Big Five” Complications After Transcatheter Aortic Valve Replacement: Do We Still Have to Be Afraid of Them?∗. JACC Cardiovasc Interv. 2019 Feb 25;12(4):370–2.
dc.relation.referencesLeon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. New England Journal of Medicine. 2010 Oct 21 ;363(17):1597–607.
dc.relation.referencesAdams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Prosthesis. New England Journal of Medicine. 2014 May 8;370(19):1790–8.
dc.relation.referencesSmith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients. New England Journal of Medicine. 2011 Jun 9;364(23):2187–98.
dc.relation.referencesRheude T, Costa G, Ribichini FL, Pilgrim T, Amat-Santos IJ, De Backer O, et al. Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2023;19(7):589–99.
dc.relation.referencesMajmundar M, Doshi R, Kumar A, Johnston D, Brockett J, Kanaa’n A, et al. Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis. EuroIntervention. 2022 Feb 1;17(15):1227–37.
dc.relation.referencesBenck KN, Nesbitt K, Dranow E, Glotzbach JP, Tandar A, Pereira SJ. Transcatheter Aortic Valve Replacement Improves Quality of Life and Ventricular Function With Low-Flow/Low-Gradient Aortic Stenosis. Journal of the Society for Cardiovascular Angiography and Interventions. 2024 Mar;3(3):101266.
dc.relation.referencesMosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of Transcatheter Aortic Valve Replacement in Patients With Paradoxical Low-Flow Low-Gradient Versus High-Gradient Aortic Stenosis and Preserved Left Ventricular Function. Circ Cardiovasc Interv. 2021 Mar 1;14(3):E010042.
dc.relation.referencesTomii D, Okuno T, Heg D, Lanz J, Praz F, Stortecky S, et al. Validation of the VARC-3 Technical Success Definition in Patients Undergoing TAVR. JACC Cardiovasc Interv. 2022 Feb 28 ;15(4):353–64.
dc.relation.referencesDai H, Fan J, He Y, Chen J, Zhou D, Yidilisi A, et al. Technical Success after Transcatheter Aortic Valve Replacement for Bicuspid versus Tricuspid Aortic Stenosis. J Clin Med. 2023 Jan 1;12(1).
dc.relation.referencesSteul JH, Abdel-Wahab M, Stankowski T, Haussig S, Woitek FJ, Gasior T, et al. VARC-3 defined outcome of valve-in-valve transcatheter aortic valve implantation in stentless compared with stented aortic bioprostheses. Clinical Research in Cardiology. 2023 Dec 11;1(3):1–11.
dc.relation.referencesMaznyczka A, Pilgrim T. Antithrombotic Treatment After Transcatheter Valve Interventions: Current Status and Future Directions. Clin Ther. 2024 Feb 1 ;46(2):122–33.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.localAcceso abiertospa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectEstenosis valvular aórtica
dc.subjectReemplazo transcateter de válvula aórtica
dc.subjectDesenlaces
dc.subjectComplicaciones
dc.subjectMortalidad
dc.subject.keywordsAortic Valve Stenosis,
dc.subject.keywordsTranscatheter Aortic Valve Replacement
dc.subject.keywordsOutcome
dc.subject.keywordsComplication
dc.subject.keywordsMortality
dc.subject.nlmWG 100
dc.titleImplante de válvula aórtica transcateter, una década de experiencia en el primer centro cardiovascular en Colombia
dc.title.translatedTranscatheter aortic valve implantation. a decade of experience at the first cardiovascular center in Colombia
dc.type.coarhttps://purl.org/coar/resource_type/c_7a1f
dc.type.coarversionhttps://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driverinfo:eu-repo/semantics/bachelorThesis
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersion
dc.type.localTesis/Trabajo de grado - Monografía - Especializaciónspa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Trabajo de grado.pdf
Tamaño:
1.01 MB
Formato:
Adobe Portable Document Format
Descargar
Bloque de licencias
Mostrando 1 - 3 de 3
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.95 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar
No hay miniatura disponible
Nombre:
Carta de autorización.pdf
Tamaño:
169.17 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
No hay miniatura disponible
Nombre:
Anexo 1 Probatus.pdf
Tamaño:
179 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar

Colecciones

Especialización en Cardiología Adultos